Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For:	[Subscribe] [Scholar Register]

Number

Cited by Other Article(s)

Kim JH, Nam HC, Kim CW, Cho HS, Yoo JS, Han JW, Jang JW, Choi JY, Yoon SK, Yang H, Bae SH, Kim S, Oh JS, Chun HJ, Jeon CH, Ahn J, Sung PS. Comparative Analysis of Atezolizumab Plus Bevacizumab and Hepatic Artery Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter, Propensity Score Study. Cancers (Basel) 2023;15:4233. [PMID: 37686509 PMCID: PMC10487133 DOI: 10.3390/cancers15174233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2023] [Revised: 08/16/2023] [Accepted: 08/22/2023] [Indexed: 09/10/2023] Open

Affiliation(s)

Ji Hoon Kim Department of Gastroenterology and Hepatology, Uijeongbu St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea; (J.H.K.); (H.-C.N.); (C.-W.K.)
Hee-Chul Nam Department of Gastroenterology and Hepatology, Uijeongbu St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea; (J.H.K.); (H.-C.N.); (C.-W.K.)
Chang-Wook Kim Department of Gastroenterology and Hepatology, Uijeongbu St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea; (J.H.K.); (H.-C.N.); (C.-W.K.)
Hee Sun Cho Department of Gastroenterology and Hepatology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea; (H.S.C.); (J.-S.Y.); (J.W.H.); (J.W.J.); (J.Y.C.); (S.K.Y.)
Jae-Sung Yoo Department of Gastroenterology and Hepatology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea; (H.S.C.); (J.-S.Y.); (J.W.H.); (J.W.J.); (J.Y.C.); (S.K.Y.)
Ji Won Han Department of Gastroenterology and Hepatology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea; (H.S.C.); (J.-S.Y.); (J.W.H.); (J.W.J.); (J.Y.C.); (S.K.Y.)
Jeong Won Jang Department of Gastroenterology and Hepatology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea; (H.S.C.); (J.-S.Y.); (J.W.H.); (J.W.J.); (J.Y.C.); (S.K.Y.)
Jong Young Choi Department of Gastroenterology and Hepatology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea; (H.S.C.); (J.-S.Y.); (J.W.H.); (J.W.J.); (J.Y.C.); (S.K.Y.)
Seung Kew Yoon Department of Gastroenterology and Hepatology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea; (H.S.C.); (J.-S.Y.); (J.W.H.); (J.W.J.); (J.Y.C.); (S.K.Y.)
Hyun Yang Department of Gastroenterology and Hepatology, Eunpyeong St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea; (H.Y.); (S.H.B.)
Si Hyun Bae Department of Gastroenterology and Hepatology, Eunpyeong St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea; (H.Y.); (S.H.B.)
Suho Kim Department of Radiology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea; (S.K.); (J.S.O.); (H.J.C.)
Jung Suk Oh Department of Radiology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea; (S.K.); (J.S.O.); (H.J.C.)
Ho Jong Chun Department of Radiology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea; (S.K.); (J.S.O.); (H.J.C.)
Chang Ho Jeon Department of Radiology, Eunpyeong St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea;
Jaegyoon Ahn Department of Computer Science & Engineering, Incheon National University, Incheon 22573, Republic of Korea
Pil Soo Sung Department of Gastroenterology and Hepatology, Uijeongbu St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea; (J.H.K.); (H.-C.N.); (C.-W.K.)

Collapse

Resistance to Antiangiogenic Therapy in Hepatocellular Carcinoma: From Molecular Mechanisms to Clinical Impact. Cancers (Basel) 2022;14:cancers14246245. [PMID: 36551730 PMCID: PMC9776845 DOI: 10.3390/cancers14246245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2022] [Revised: 12/08/2022] [Accepted: 12/10/2022] [Indexed: 12/23/2022] Open

Tanaka T, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Kaibori M, Hiasa Y, Kudo M, Kumada T. Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice. Hepatol Res 2022;52:773-783. [PMID: 35633504 DOI: 10.1111/hepr.13797] [Citation(s) in RCA: 32] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/25/2022] [Revised: 05/07/2022] [Accepted: 05/19/2022] [Indexed: 12/23/2022]

Abstract

BACKGROUND/AIM

Atezolizumab plus bevacizumab (Atez/Bev) treatment is recommended for unresechepatocellular carcinoma (u-HCC) patients classified as Child-Pugh A (CP-A). This study aimed to elucidate the prognosis of patients treated with Atez/Bev, especially CP-A and -B cases.

MATERIALS/METHODS

From September 2020 to March 2022, 457 u-HCC patients treated with Atez/Bev were enrolled (median age 74 years, male:female = 368:89, CP-A:CP-B = 427:30, Child-Pugh score [CPS] 5:6:7:8:9 = 271:156:21:8:1). Therapeutic response was evaluated using RECIST ver.1.1. Clinical features and prognosis were retrospectively evaluated.

RESULTS

There were no significant differences between CP-A and -B patients in regard to best response (CR:PR:SD:PD = 16:91:194:81 vs. 0:7:13:8, p = 0.739; objective response rate/disease control rate = 28.0%/78.8% vs. 25.0%/71.4%). Analysis performed using inverse probability weighting adjustments of clinical factors other than those related to hepatic reserve function with a p value < 0.10 for comparisons between patients with CP-A and -B showed that the progression-free survival (PFS) rate for CP-A cases was better (6-/12-/18-month: 58.2%/36.1%/27.8% vs. 49.6%/8.7%/non-estimable [NE], p < 0.001), as was overall survival (OS) rate (6-/12-/18-month: 89.9%/71.7%/51.4% versus 63.6%/18.4%/NE; p < 0.001). Median PFS (mPFS) and median OS (mOS) for the CPS-5 were 9.5 months/NE, and 5.1/14.0 months for the CPS-6 (both p < 0.001). Furthermore, for modified albumin-bilirubin grade (mALBI)-1/2a/2b, mPFS was 9.4/8.5/5.3 months (p < 0.001) and mOS was NE/17.8/13.4 months (p < 0.001).

CONCLUSION

Better hepatic function, such as mALBI grade 1 or 2a are thought to indicate a better condition for obtaining sufficient prognosis with Atez/Bev treatment for u-HCC patients, whereas for CP-B patients, who mainly shown an mALBI grade of 2b or 3, Atez/Bev might have less therapeutic efficacy.

Collapse

Affiliation(s)

Takaaki Tanaka Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan
Atsushi Hiraoka Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan
Toshifumi Tada Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan
Masashi Hirooka Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan
Kazuya Kariyama Department of Hepatology, Okayama City Hospital, Okayama, Japan
Joji Tani Department of Gastroenterology and Hepatology, Kagawa University, Kagawa, Japan
Masanori Atsukawa Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan
Koichi Takaguchi Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan
Ei Itobayashi Department of Gastroenterology, Asahi General Hospital, Asahi, Japan
Shinya Fukunishi Department of Gastroenterology, Osaka Medical and Pharmaceutical University, Osaka, Japan
Kunihiko Tsuji Center of Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan
Toru Ishikawa Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan
Kazuto Tajiri Department of Gastroenterology, Toyama University Hospital, Toyama, Japan
Hironori Ochi Hepato-biliary Center, Japanese Red Cross Matsuyama Hospital, Matsuyama, Japan
Satoshi Yasuda Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan
Hidenori Toyoda Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan
Chikara Ogawa Department of Gastroenterology, Japanese Red Cross Takamatsu Hospital, Takamatsu, Japan
Takashi Nishimura Department of Gastroenterology and Hepatology, Hyogo College of Medicine, Nishinomiya, Japan
Takeshi Hatanaka Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Gunma, Japan
Satoru Kakizaki Department of Clinical Research, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan
Noritomo Shimada Division of Gastroenterology and Hepatology, Otakanomori Hospital, Kashiwa, Japan
Kazuhito Kawata Hepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Japan
Atsushi Naganuma Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan
Hisashi Kosaka Department of Surgery, Kansai Medical University, Hirakata, Japan
Hideko Ohama Department of Gastroenterology, Osaka Medical and Pharmaceutical University, Osaka, Japan
Kazuhiro Nouso Department of Hepatology, Okayama City Hospital, Okayama, Japan
Asahiro Morishita Department of Gastroenterology and Hepatology, Kagawa University, Kagawa, Japan
Akemi Tsutsui Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan
Takuya Nagano Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan
Norio Itokawa Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan
Tomomi Okubo Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan
Taeang Arai Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan
Michitaka Imai Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan
Yohei Koizumi Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan
Shinichiro Nakamura Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan
Kouji Joko Hepato-biliary Center, Japanese Red Cross Matsuyama Hospital, Matsuyama, Japan
Hiroko Iijima Department of Gastroenterology and Hepatology, Hyogo College of Medicine, Nishinomiya, Japan
Masaki Kaibori Department of Surgery, Kansai Medical University, Hirakata, Japan
Yoichi Hiasa Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan
Masatoshi Kudo Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan
Takashi Kumada Department of Nursing, Gifu Kyoritsu University, Ogaki, Japan

Collapse

Fulgenzi CAM, D'Alessio A, Ogunbiyi O, Demirtas CO, Gennari A, Cortellini A, Sharma R, Pinato DJ. Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape? Expert Opin Investig Drugs 2022;31:681-691. [PMID: 35507361 DOI: 10.1080/13543784.2022.2072726] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]